Compile Data Set for Download or QSAR
Report error Found 135 Enz. Inhib. hit(s) with all data for entry = 10603
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554105(US11325916, Example 131)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554104(US11325916, Example 130)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554107(US11325916, Example 133)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554109(US11325916, Example 135)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554108(US11325916, Example 134)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554089(US11325916, Example 115)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554088(US11325916, Example 114)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554091(US11325916, Example 117)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554090(US11325916, Example 116)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554093(US11325916, Example 119)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554092(US11325916, Example 118)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554095(US11325916, Example 121)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554094(US11325916, Example 120)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554097(US11325916, Example 123)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554096(US11325916, Example 122)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554099(US11325916, Example 125)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554098(US11325916, Example 124)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554101(US11325916, Example 127)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554100(US11325916, Example 126)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554103(US11325916, Example 129)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554102(US11325916, Example 128)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553972(US11325916, Example 3)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553971(US11325916, Example 2)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553974(US11325916, Example 5 | US11325916, Example 6)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553973(US11325916, Example 4)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553976(US11325916, Example 7)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553974(US11325916, Example 5 | US11325916, Example 6)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553978(US11325916, Example 9)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553977(US11325916, Example 8)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553980(US11325916, Example 11)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553982(US11325916, Example 13)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553981(US11325916, Example 12)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553984(US11325916, Example 15)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553983(US11325916, Example 14)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553986(US11325916, Example 17)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553985(US11325916, Example 16)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553970(US11325916, Example 1)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554007(US11325916, Example 35)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554006(US11325916, Example 34)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554009(US11325916, Example 37)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554008(US11325916, Example 36)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554012(US11325916, Example 39)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554011(US11325916, Example 38)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554014(US11325916, Example 41)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554013(US11325916, Example 40)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554016(US11325916, Example 43)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554015(US11325916, Example 42)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554018(US11325916, Example 45)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554017(US11325916, Example 44)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554020(US11325916, Example 47)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
US Patent

Displayed 1 to 50 (of 135 total ) | Next | Last >>
Jump to: